Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone.

Simple item page
dc.contributor.authorEdstein, M Den_US
dc.contributor.authorLooareesuwan, Sen_US
dc.contributor.authorViravan, Cen_US
dc.contributor.authorKyle, D Een_US
dc.date.accessioned2009-05-27T15:02:04Z
dc.date.available2009-05-27T15:02:04Z
dc.date.issued1996-06-01en_US
dc.descriptionThe Southeast Asian Journal of Tropical Medicine and Public Health.en_US
dc.description.abstractClinical studies have shown atovaquone (ATQ), a new blood schizontocidal drug, in combination with proguanil (PROG) to be very effective in the treatment of acute multidrug-resistant falciparum malaria. The multiple dose pharmacokinetics of PROG were determined in Thai patients with acute falciparum malaria given PROG alone (200 mg PROG twice a day for 3 days, n = 4) and concurrently PROG and ATQ (200 mg PROG and 500 mg ATQ twice a day for 3 days, n = 12). There were no statistical differences (p > 0.05) in the area under the plasma drug concentration-time curve (AUC), apparent oral clearance (CL/F) and elimination half-life (t1/2) of PROG between patients given PROG alone and PROG/ ATQ. The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6). The CL/F and t1/2 of PROG in the Thai patients treated with the 2 treatment regimens were also comparable to values reported in healthy Thai volunteers given a standard prophylactic dose (200 mg PROG). The results of this preliminary study suggest that ATQ is unlikely to affect the pharmacokinetics of PROG to a clinically important extent at an ATQ dosage of 500 mg twice a day for 3 days in malaria infected patients.en_US
dc.description.affiliationArmy Malaria Research Unit, Sydney, Australia.en_US
dc.identifier.citationEdstein MD, Looareesuwan S, Viravan C, Kyle DE. Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. The Southeast Asian Journal of Tropical Medicine and Public Health. 1996 Jun; 27(2): 216-20en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/31741
dc.language.isoengen_US
dc.source.urihttps://www.tm.mahidol.ac.th/seameo/publication.htmen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntimalarials --pharmacokineticsen_US
dc.subject.meshAtovaquoneen_US
dc.subject.meshChloroguanide --pharmacokineticsen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDrug Resistance, Multipleen_US
dc.subject.meshDrug Synergismen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshHumansen_US
dc.subject.meshIntestinal Absorptionen_US
dc.subject.meshMalaria, Falciparum --drug therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMetabolic Clearance Rateen_US
dc.subject.meshNaphthoquinones --pharmacokineticsen_US
dc.titlePharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone.en_US
dc.typeClinical Trialen_US
dc.typeClinical Trial, Phase IIen_US
dc.typeComparative Studyen_US
dc.typeControlled Clinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Southeast Asian Journal of Tropical Medicine and Public Health